App-Quantinova.ai

Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma

Rahul Shrimanker - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Time is Essential for Competant Inhaler Technique Training

Bhavin Mehta - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Opinions on the environmental impact of inhaler devices in UK respiratory care

Harriet Lewis - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

The bronchial expression of vanin in moderate to severe asthma

Andrew Higham - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Calcium-sensing receptor (CaSR) drives lung ECM remodelling and fibrosis in murine asthma models and in ageing mice

Richard Bruce - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Late Breaking Abstract - Impact of multi-disciplinary involvement on smoking cessation in the acute admissions unit (AMU)

Ravijyot Saggu - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Respiratory point of care testing (R-POCT) to facilitate diagnosis and treatment in the community for COPD exacerbations

Kay Roy - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

A preliminary study to determine the effects of nebulised salbutamol on blood glucose levels during an acute asthma exacerbation

Craig Mortimer - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Salbutamol

In-vitro product performance of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) delivered from a dry powder inhaler (DPI) using the Electronic Lung (EL) to replicate patient inhalation profiles

David Prime - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Fluticasone furoate

Adherence to steroid treatment in asthma

Matthew Jones - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Prednisolone

Treatment compliance in patients with Asthma, COPD and Mixed Asthma-COPD

Francisco Guillermo Puig S�nchez - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

Bronchial Thermoplasty leads to rapid and persistent improvements in airway remodeling

Richard Russell - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Late Breaking Abstract - An assessment of potential predictive biomarkers for the treatment of severe eosinophilic asthma with CRTH2 antagonists

Yuan Ye - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Late Breaking Abstract - Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma

Ingmar Bruns - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Nitric oxide

Markers of eosinophilic inflammation are associated with response to the DP2 antagonist GB001 in patients with mild atopic asthma

Hector Ortega - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study)

Tim Harrison - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Budesonide

Exacerbation risk after night-time waking due to asthma in SYGMA 1

Helen Reddel - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Terbutaline

Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma

Mark Fitzgerald - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Terbutaline

Late Breaking Abstract - High blood neutrophils are associated with increased exacerbations and mortality in Chronic Obstructive Pulmonary Disease

Mike Lonergan - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Improvements in Clinical Outcomes Associated with Reduction in Hyperinflation with Zephyr Valves

Frank Sciurba - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Filters

45280 Abstracts